FDA Approves Erzofri (paliperidone palmitate) for the Treatment …
WEBErzofri, administered once a month, is the first patented paliperidone palmitate long-acting injection developed in China to get approved in the U.S. The product was granted a U.S. patent (Patent No.11,666,573) in 2023, which will expire in 2039.
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™
WEBSep 1, 2021 · Innovative Medicine. Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™. (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia. INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication.
FDA Approves First Six-Month LAI Antipsychotic - Psychiatric News
WEBNov 29, 2021 · The “long” in long-acting injectable (LAI) antipsychotics extended its reach this past fall, as the U.S. Food and Drug Administration (FDA) approved the first twice-yearly injectable of paliperidone palmitate (marketed as Invega Hafyera by Janssen). Prior to this approval, the longest coverage offered by an LAI was three months.
FDA Approves Erzofri for the Treatment of Schizophrenia and ...
WEBJul 30, 2024 · The US Food and Drug Administration (FDA) has approved Luye Pharma’s paliperidone palmitate (Erzofri) extended-release injectable suspension for the treatment of schizophrenia in adults and schizoaffective disorder in adults as monotherapy, as well as an adjunct to mood stabilizers or antidepressants. 1
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6 …
WEBTITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting...
First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA ...
WEBSep 1, 2021 · The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting atypical antipsychotic Invega Hayfera (6-month paliperidone palmitate), a one-of-a-kind twice-yearly injectable for the treatment of adults with schizophrenia. 1 Patients wishing to take Invega Hayfera must first be …
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone …
WEBJul 28, 2024 · ERZOFRI, administered once a month, is the first patented paliperidone palmitate long-acting injection developed in China to get approved in the U.S. The product was granted a U.S. patent (Patent...
FDA Approves Paliperidone Palmitate for Schizophrenia, …
WEBJul 31, 2024 · Luye Pharma Group announced on July 29, 2024, that the US Food and Drug Administration (FDA) approved paliperidone palmitate (ERZOFRI), an extended-release injectable suspension for the treatment of schizophrenia and schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants. 1.
Paliperidone Palmitate Demonstrates Long-Term Efficacy, Safety …
WEBAug 13, 2024 · Over 95% of patients with schizophrenia receiving long-acting injectable (LAI) paliperidone palmitate, administered twice a year, remained relapse-free for up to 3 years, according to study...
Paliperidone to Treat Psychotic Disorders - PMC - National …
WEBJul 28, 2021 · Paliperidone was granted approval in the United States in 2006 to be used in the treatment of schizophrenia and in 2009 for schizoaffective disorder. Summary: Schizophrenia and schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and negative symptoms.